TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

This is a multicentre, randomized, double-blind, active-controlled Phase 2a study evaluating TriGlytza®-01 in adults with Type 2 diabetes inadequately controlled on metformin therapy. Eligible participants will be randomized in a 1:1:1 ratio to metformin alone, low-dose TriGlytza®-01, or high-dose TriGlytza®-01. Treatment will continue for 16 weeks following screening. The study will evaluate safety, tolerability, glycaemic efficacy, body weight, pharmacokinetics, and selected metabolic biomarkers.

Inclusion criteria

Adults aged 18 to 70 years. Confirmed diagnosis of Type 2 diabetes mellitus. Inadequate glycaemic control while receiving a stable dose of metformin.

Inclusion criteria

• Adults aged 18 to 70 years.
• Confirmed diagnosis of Type 2 diabetes mellitus.
• Inadequate glycaemic control while receiving a stable dose of metformin.
• HbA1c within the protocol-defined screening range.
• Body mass index (BMI) 25 to 40 kg/m².
• Adequate renal function.
• Able and willing to provide written informed consent and comply with study procedures.

Exclusion criteria

• Type 1 diabetes mellitus or history of diabetic ketoacidosis.
• Use of prohibited glucose-lowering medications before screening.
• Clinically significant renal, hepatic, gastrointestinal, cardiovascular, or other medical conditions that could interfere with study participation or safety.
• Recent major cardiovascular event or unstable cardiovascular disease.
• Previous bariatric surgery or recent treatment with anti-obesity medication.
• Active infection or other uncontrolled medical condition.
• Pregnant or breastfeeding, or unwilling to comply with protocol-required contraception.
• Any condition that, in the investigator's opinion, would make participation unsuitable or compromise the study.